Data from the RATIONALE 305 trial support the approval of tislelizumab/chemotherapy in unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.
Approval Alert | Tislelizumab/Chemotherapy in Gastric/GEJ Adenocarcinoma
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
2
Single-Agent PD-1 Blockade Therapy Improves Responses in Desmoplastic Melanoma
3
64Cu-SAR-bisPSMA PET Detects More Prostate Cancer Lesions vs SOC
4
Real-World Data From IMS: Promising Results in Relapsed/Refractory Multiple Myeloma
5
